Infectious risk stratification in multiple sclerosis patients receiving immunotherapy

The increasing number of potent treatments for multiple sclerosis warrants screening for infections. To investigate the prevalence of infections in two independent German patient cohorts with multiple sclerosis/neuromyelitis optica spectrum disorders (NMOSD), we performed a retrospective chart revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Jonas, Leussink, Verena I., Dehmel, Thomas, Ringelstein, Marius, Goebels, Norbert, Adams, Ortwin, MacKenzie, Colin R., Warnke, Clemens, Feldt, Torsten, Lammerskitten, Anna, Klotz, Luisa, Meuth, Sven, Wiendl, Heinz, Hartung, Hans‐Peter, Aktas, Orhan, Albrecht, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740259/
https://www.ncbi.nlm.nih.gov/pubmed/29296620
http://dx.doi.org/10.1002/acn3.491
Descripción
Sumario:The increasing number of potent treatments for multiple sclerosis warrants screening for infections. To investigate the prevalence of infections in two independent German patient cohorts with multiple sclerosis/neuromyelitis optica spectrum disorders (NMOSD), we performed a retrospective chart review study of multiple sclerosis/NMOSD patients who underwent testing for infections between 2014 and 2016. We show that 6 out of 80 tested patients (Düsseldorf cohort) and 2 out of 97 tested patients (Münster cohort) had a latent tuberculosis infection; total 3.95%, 95% CI: 2–8%. Our findings suggest that latent tuberculosis infection is frequent (>1%). Screening should be performed before embarking on immunomodulatory therapies to allow treatment and mitigation of the risk of a reactivation.

Ejemplares similares